Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06088888
Other study ID # TGRX-678-07-101
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date June 15, 2024
Est. completion date June 30, 2027

Study information

Verified date May 2024
Source Shenzhen TargetRx, Inc.
Contact Xinyi Zhu
Phone 86-13061651609
Email xinyi.zhu@tjrbiosciences.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this single-arm, open-label, dose escalation + cohort expansion study is to evaluate the safety, tolerability, pharmacokinetic and preliminary efficacy of TGRX-678 in Chronic Myelogenous Leukemia patients who had failure with or are intolerant to TKI treatments.


Description:

This is the first trial with TGRX-678 conducted to US patients which aims to evaluate the safety profile and preliminary efficacy profile in advanced or refractory CML patients with previous failure or intolerance to TKI treatments. The primary purpose of this study is to evaluate the safety profile of TGRX-678, including determination of the recommended dose for expansion (RDE) and other safety measures of the investigational drug, such as adverse events and abnormal clinical outcomes. Preliminary efficacy profile of TGRX-678 is evaluated based on the changes in peripheral blood cells and disease-associated cytogenetic and molecular markers. Recommended Phase II dose (RP2D) will be determined at end of the study considering safety, tolerability, pharmacokinetic and efficacy data.


Recruitment information / eligibility

Status Recruiting
Enrollment 90
Est. completion date June 30, 2027
Est. primary completion date March 30, 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Willing to participate in the study with informed consent; - At least 18 years of age at the time of screening; - Any sex; - Diagnosis of CML-CPduring the screening period; - Intolerant or resistant to TKI treatments; - Eastern Cooperative Oncology Group (ECOG) performance status = 2; - Adequate Absolute neutrophil count (ANC), hemoglobin and platelets levels; - Adequate renal and liver function; - Normal corrected QT (QTcF) interval as indicated by electrocardiogram (ECG) screening results; - Negative blood pregnancy test results for female patients of childbearing potential. - Willing to take highly effective contraceptive measures throughout the trial and for 6 months after last dose of investigational drug for female subjects of child-bearing potential or male subject with female partner of child-bearing potential. Exclusion Criteria: - Exposure to other antineoplastic therapies prior to study enrollment; - Exposure to other investigational agent(s) within 14 days of initiating TGRX-678 therapy; - Ongoing toxicity from prior therapy greater than grade 1 by CTCAE v. 3 (except alopecia); - Hematopoietic cell transplantation < 60 days prior to the first dose; - Evidence of graft versus host disease (GVHD), whether or not requiring immunosuppressive therapy; - Concomitant immunosuppressive therapy (other than short-term corticosteroid treatment); - Exposure to drugs related to torsade de pointes; - Cytological or pathological diagnosis of active central nervous system disorder; - Significant or uncontrolled cardiovascular diseases as defined in the full clinical protocol; - Having long QT syndrome, or with family history of idiopathic sudden death or congenital long QT syndrome; - Uncontrolled hypertension; - Receipt of Traditional Chinese medication or herbal preparations indicated for anti-cancer purposes within 2 weeks prior to the first dose; - Severe hemorrhagic disorders unrelated to CML; - History of pancreatitis; - History of excessive alcohol use; - History of elevation in amylase or lipase within 1 year; - Have Grade 2 or worse interstitial lung disease or interstitial pneumonitis within 4 weeks prior to Screening; - Uncontrolled hypertriglyceridemia; - Malabsorption syndrome or other illness that could affect oral absorption. - Diagnosis of another primary malignancy in the past 3 years; - Reception of major surgery within 14 days prior to the first dose; - Active infections that require systemic treatment or other severe infections within 14 days prior to enrollment; - Known human immunodeficiency virus (HIV) positive; acute or chronic liver disease (including chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections); - Have received or will receive a COVID-19 vaccine within 14 days of study enrollment; - Have a positive reverse transcriptase polymerase chain reaction (RT-PCR) test result for SARS-CoV-2 within 2 weeks prior to Screening; - Pregnant or breastfeeding female; - Female patient of child-bearing potential or male patient who have female partners of child-bearing potential that is unable or unwilling to take highly effective contraceptive measures during the trial and for 6 months after last dose of investigational drug; - Significant organ dysfunction that could compromise the patient's safety or the evaluation of the drug's safety in the opinion of the investigator or the medical monitor; - Any condition makes participation in this trial inappropriate in the opinion of the investigator or medical monitor;

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
TGRX-678
Participants are given TGRX-678 tablets orally, once daily, at one of the dose levels as pre-determined for the dose escalation sequence or expansion cohorts.

Locations

Country Name City State
United States The University of Texas MD Anderson Cancer Center Houston Texas
United States Fred Hutchinson Cancer Center Seattle Washington

Sponsors (2)

Lead Sponsor Collaborator
Shenzhen TargetRx, Inc. M.D. Anderson Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Recommended dose for expansion (RDE) To determine the RDE of TGRX-678 in CML patients to be applied in Cohort Expansion part of the study Time Frame: At end of Dose Escalation part of study, an average of 1 year
Primary Safety profile (DLT) to record and analyse subjects with dose-limiting toxicities (DLTs) Time Frame: DLT: collect during Cycle 1 (28 days)
Primary Safety profile (AEs/SAEs) to record and analyse subjects with adverse events (AEs) and serious adverse events (SAEs) AE and SAE: through completion of the study, an average of 2 years
Primary Recommended phase II dose (RP2D) To determine the RP2D of TGRX-678 in CML patients for Phase II At completion of the study, an average of 2 years
Secondary Hematologic Response To record and analyse the hematologic response of subjects. Subjects will be determined whether complete hematologic response (CHR) or no evidence of leukemia (NEL) is reached. at screening period, weekly in Cycle 1, bi-weekly in Cycle 2 and monthly starting from Cycle 3 (each cycle is 28 days), an average of 1.5 years
Secondary Cytogenetic Response To record and analyse the cytogenetic response of subjects subjects will be determined whether partial or complete cytogenetic response (Ph+ < 35%) is reached. at screening period, end of every 3 Cycles (each cycle is 28 days), an average of 1.5 years
Secondary Molecular Response To record and analyse the molecular response of subjects Subjects will be determined whether major molecular response (BCR-ABL1 (IS) no more than 0.1%) is reached. at screening period, end of every 3 Cycles (each cycle is 28 days), an average of 1.5 years
Secondary Plasma Cmax Cmax of TGRX-678 as measured in plasma Day 1, 7, 21, 28 of Cycle 1, and Day 28 of Cycle 2, 3 and 5 (each cycle is 28 days)
Secondary Plasma Tmax Tmax of TGRX-678 as measured in plasma Day 1, 7, 21, 28 of Cycle 1, and Day 28 of Cycle 2, 3 and 5 (each cycle is 28 days)
Secondary Plasma T1/2 T1/2 of TGRX-678 as measured in plasma Day 1, 7, 21, 28 of Cycle 1, and Day 28 of Cycle 2, 3 and 5 (each cycle is 28 days)
Secondary Plasma AUClast AUClast of TGRX-678 as measured in plasma Day 1, 7, 21, 28 of Cycle 1, and Day 28 of Cycle 2, 3 and 5 (each cycle is 28 days)
Secondary Plasma AUCinf AUCinf of TGRX-678 as measured in plasma Day 1, 7, 21, 28 of Cycle 1, and Day 28 of Cycle 2, 3 and 5 (each cycle is 28 days)
Secondary Plasma Cmin Cmin of TGRX-678 as measured in plasma Day 1, 7, 21, 28 of Cycle 1, and Day 28 of Cycle 2, 3 and 5 (each cycle is 28 days)
Secondary Plasma AUCss AUCss of TGRX-678 as measured in plasma Day 1, 7, 21, 28 of Cycle 1, and Day 28 of Cycle 2, 3 and 5 (each cycle is 28 days)
Secondary Plasma Cmax,ss steady state Cmax of TGRX-678 as measured in plasma Day 1, 7, 21, 28 of Cycle 1, and Day 28 of Cycle 2, 3 and 5 (each cycle is 28 days)
Secondary Plasma Tmax,ss steady state Tmax of TGRX-678 as measured in plasma Day 1, 7, 21, 28 of Cycle 1, and Day 28 of Cycle 2, 3 and 5 (each cycle is 28 days)
Secondary CL (Clearance) Clearance of TGRX-678 as measured in plasma Day 1, 7, 21, 28 of Cycle 1, and Day 28 of Cycle 2, 3 and 5 (each cycle is 28 days)
Secondary Vd (Volume of distribution) Volume of distribution of TGRX-678 as measured in plasma Day 1, 7, 21, 28 of Cycle 1, and Day 28 of Cycle 2, 3 and 5 (each cycle is 28 days)
See also
  Status Clinical Trial Phase
Recruiting NCT05088356 - Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft Phase 1
Recruiting NCT04904588 - HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide Phase 2
Completed NCT02592447 - Cognitive Behavioral Intervention for Targeted Therapy Fatigue (CBT-TTF) Intervention N/A
Withdrawn NCT04282174 - CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies Phase 2
Terminated NCT01397734 - Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML) Phase 1
Completed NCT00975975 - Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer Phase 2
Withdrawn NCT01011998 - A Study of Imatinib and Valproic Acid in Patients With Chronic Myelogenous Leukemia (CML) Phase 2
Completed NCT00378534 - Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants Phase 2
Completed NCT00098033 - Investigation of Clofarabine in Acute Leukemias Phase 2
Terminated NCT00852709 - Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute Leukemias Phase 1
Completed NCT02581007 - Reduced Intensity Conditioning Transplant Using Haploidentical Donors Phase 2
Terminated NCT03547154 - Polyethylene Glycol Interferon Alfa-2b (PEG Intron) Versus Interferon Alfa-2b (INTRON^® A) in the Treatment of Newly Diagnosed Chronic Myelogenous Leukemia (CML) (C98026) Phase 2/Phase 3
Terminated NCT02709083 - Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia Phase 2
Terminated NCT02145039 - Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases N/A
Terminated NCT02146846 - Population Pharmacokinetics of Imatinib in CML Patients in Iran N/A
Active, not recruiting NCT01036009 - A Study of Withdrawal of Immunosuppression and Donor Lymphocyte Infusions Following Allogeneic Transplant for Pediatric Hematologic Malignancies Phase 2
Completed NCT00990587 - Study Evaluating the Tolerance and Biologic Activity of Oral Ciclopirox Olamine in Patients With Relapsed or Refractory Hematologic Malignancy Phase 1
Terminated NCT00594308 - In-Vivo Activated T-Cell Depletion to Prevent GVHD N/A
Terminated NCT00500006 - A Phase I Dose Escalation Combination Study in Patients With Chronic Myelogenous Leukemia (CML) and Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)(0457-009)(TERMINATED) Phase 1
Completed NCT00493181 - Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients Phase 2